Skip to content
Checking whether you are signed in

Amgen Inc.

AMGNNasdaqFull coverage

Price
Loading your watchlists

AI-generatedPublished Nov 8, 2026, 11:24 AM UTC

Q3 fiscal 2026 edition

A free account unlocks one dossier edition a month.

Create a free account

Already have an account? Sign in

Summary

Free to read

Amgen sells biologic medicines for heart disease, bone loss, inflammation, rare autoimmune diseases and cancer, mostly in the United States. In the third quarter of fiscal 2026 its six fast-growing brands, led by Repatha, added $1,290 million of sales against a loss of $831 million on four maturing brands, so product sales grew 8% even as Prolia and XGEVA fell 45% to biosimilars. Earnings growth was smaller than the headline: a lower tax rate supplied part of the 14% rise in non-GAAP EPS, and GAAP profit includes large gains on the BeOne stake. Moatsight estimates revenue of about $40.5 billion over the next four quarters, with the obesity candidate MariTide, still without Phase 3 data, a smaller part of the outlook than the next wave of patent expiries from 2028.

In the full dossier

  1. Part 1In brief
  2. Part 2Business explainer
  3. Part 3Earnings
  4. Part 4Valuation and projections
  5. Part 5What changed

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers